These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38616658)

  • 1. A Path to Persistence after EGFR Inhibition.
    Rumde PH; Burns TF
    Cancer Res; 2024 Apr; 84(8):1188-1190. PubMed ID: 38616658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.
    Hu B; Wiesehöfer M; de Miguel FJ; Liu Z; Chan LH; Choi J; Melnick MA; Arnal Estape A; Walther Z; Zhao D; Lopez-Giraldez F; Wurtz A; Cai G; Fan R; Gettinger S; Xiao A; Yan Q; Homer R; Nguyen DX; Politi K
    Cancer Res; 2024 Apr; 84(8):1303-1319. PubMed ID: 38359163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.
    Yochum ZA; Cades J; Wang H; Chatterjee S; Simons BW; O'Brien JP; Khetarpal SK; Lemtiri-Chlieh G; Myers KV; Huang EH; Rudin CM; Tran PT; Burns TF
    Oncogene; 2019 Jan; 38(5):656-670. PubMed ID: 30171258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
    Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K
    Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer.
    Yi Y; Li P; Huang Y; Chen D; Fan S; Wang J; Yang M; Zeng S; Deng J; Lv X; Luo K; He Z; Liu H
    Oncogene; 2022 Sep; 41(37):4318-4329. PubMed ID: 35986102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer.
    Lee J; Kim HS; Lee B; Kim HK; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Cancer; 2020 Jun; 126(11):2704-2712. PubMed ID: 32154925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
    Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).
    Cardona AF; Ruiz-Patiño A; Recondo G; Martín C; Raez L; Samtani S; Minata JN; Blaquier JB; Enrico D; Burotto M; Ordóñez-Reyes C; Chamorro DF; Garcia-Robledo JE; Corrales L; Zatarain-Barrón ZL; Más L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Mejía S; Jaller E; Vargas C; Carranza H; Otero J; Rodríguez J; Archila P; Bermudez M; Gamez T; Cordeiro de Lima V; Freitas H; Russo A; Polo C; Malapelle U; Perez DM; Rolfo C; Viola L; Rosell R; Arrieta O
    Clin Lung Cancer; 2022 Sep; 23(6):522-531. PubMed ID: 35798634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AXIN1/MYC Axis Mediated the Osimertinib Resistance in EGFR Mutant Non-Small Cell Lung Cancer Cells.
    Yu H; Wang Z; Dong Y; Li L; Fan X; Zheng N; Jiang J; Lin C; Lu C; Li K; Feng M
    Tohoku J Exp Med; 2024 May; 262(4):269-276. PubMed ID: 38233113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notch pathway regulates osimertinib drug-tolerant persistence in EGFR-mutated non-small-cell lung cancer.
    Takahashi H; Sakakibara-Konishi J; Furuta M; Shoji T; Tsuji K; Morinaga D; Kikuchi E; Kikuchi J; Noguchi T; Hatanaka KC; Hatanaka Y; Shinagawa N; Konno S
    Cancer Sci; 2023 Apr; 114(4):1635-1650. PubMed ID: 36411521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.
    Kiritani A; Amino Y; Uchibori K; Akita T; Harutani Y; Ogusu S; Tsugitomi R; Manabe R; Ariyasu R; Kitazono S; Yanagitani N; Nishio M
    Thorac Cancer; 2024 Feb; 15(5):402-409. PubMed ID: 38226415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report.
    Ren KH; Qin WW; Wang Y; Peng JC; Hu WX
    Ann Palliat Med; 2022 Jul; 11(7):2503-2509. PubMed ID: 35927783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
    Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.
    Liu K; Chen X; Wu L; Chen S; Fang N; Cai L; Jia J
    BMC Pulm Med; 2021 May; 21(1):163. PubMed ID: 33992097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.
    La Monica S; Minari R; Cretella D; Flammini L; Fumarola C; Bonelli M; Cavazzoni A; Digiacomo G; Galetti M; Madeddu D; Falco A; Lagrasta CA; Squadrilli A; Barocelli E; Romanel A; Quaini F; Petronini PG; Tiseo M; Alfieri R
    J Exp Clin Cancer Res; 2019 May; 38(1):222. PubMed ID: 31138260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
    Martinez-Marti A; Felip E; Matito J; Mereu E; Navarro A; Cedrés S; Pardo N; Martinez de Castro A; Remon J; Miquel JM; Guillaumet-Adkins A; Nadal E; Rodriguez-Esteban G; Arqués O; Fasani R; Nuciforo P; Heyn H; Villanueva A; Palmer HG; Vivancos A
    Ann Oncol; 2017 Oct; 28(10):2451-2457. PubMed ID: 28961841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study.
    Araki T; Kanda S; Obara M; Agatsuma T; Kakizaki Y; Hama M; Yamamoto H; Takada M; Yamamoto M; Matsuo A; Kondo D; Komatsu M; Sonehara K; Tateishi K; Hanaoka M; Koizumi T
    Respir Investig; 2024 Mar; 62(2):262-268. PubMed ID: 38245931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC.
    Lee EJ; Oh SY; Lee YW; Kim JY; Kim MJ; Kim TH; Lee JB; Hong MH; Lim SM; Baum A; Woelflingseder L; Engelhardt H; Petronczki M; Solca F; Yun MR; Cho BC
    Clin Cancer Res; 2024 Apr; 30(8):1582-1594. PubMed ID: 38330145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines.
    Ji W; Choi YJ; Kang MH; Sung KJ; Kim DH; Jung S; Choi CM; Lee JC; Rho JK
    Cells; 2020 Dec; 9(12):. PubMed ID: 33287368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.